Welcome to the Utah Chapter of the American College of Cardiology
|
Ed Miner, MD, FACC Utah, Chapter President ACC Governor, Utah |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!. For more information and to register, please visit:
ACC Rockies Chapter Meeting 2025
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- Could Site Selection Improve Representation in Coronary Stent PMA Studies?Premarket approval (PMA) studies for coronary stents were found to not fully reflect the intended-use population (IUP) due to significant underrepresentation of minority participants and modest underrepresentation of women, according to research on the enrollment implications of site selection published April 29 in JACC.
- Heart Failure Trials Featured at ACC.26ACC.26 featured several late-breaking heart failure clinical trials, including two focused on subgroups of heart failure that until now had limited data to guide therapies.
- NOBLE: Is PCI Equally as Safe as CABG For Patients With Unprotected Left Main CAD?No significant difference was observed in all-cause mortality at 10 years between PCI and CABG in patients with unprotected left main coronary artery disease (CAD) and no additional complex lesions, according to the final results of the NOBLE study published April 4 in The Lancet.
- Keeping it Simple: Top 10 Things to Know About the 2026 Dyslipidemia GuidelineIn this interview, Kim Allan Williams, Sr., MD, MACC and Roger S. Blumenthal, MD, FACC discuss key takeaways from the 2026 Dyslipidemia Guideline.
- Implications of ACC.26 Prevention Trials For Future GuidelinesThe VESALIUS-CV trial primary prevention analysis was a prespecified evaluation of use of evolocumab in 3,655 trial participants who had elevated LDL cholesterol (LDL-C) values but no evidence of significant atherosclerotic cardiovascular disease (ASCVD), defined as no prior revascularization, no arterial stenosis...